EA202191345A1 - Стабильный состав глюкокортикоидов - Google Patents

Стабильный состав глюкокортикоидов

Info

Publication number
EA202191345A1
EA202191345A1 EA202191345A EA202191345A EA202191345A1 EA 202191345 A1 EA202191345 A1 EA 202191345A1 EA 202191345 A EA202191345 A EA 202191345A EA 202191345 A EA202191345 A EA 202191345A EA 202191345 A1 EA202191345 A1 EA 202191345A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glucocorticoids
stable composition
glucocorticoid
preservatives
relates
Prior art date
Application number
EA202191345A
Other languages
English (en)
Russian (ru)
Inventor
Тереза Деишер
Адальберт Джарзина
Айэн Данкэн
Original Assignee
Авм Байотекнолоджи, Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авм Байотекнолоджи, Ллс filed Critical Авм Байотекнолоджи, Ллс
Publication of EA202191345A1 publication Critical patent/EA202191345A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EA202191345A 2018-11-14 2019-11-14 Стабильный состав глюкокортикоидов EA202191345A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767448P 2018-11-14 2018-11-14
PCT/US2019/061363 WO2020102474A1 (en) 2018-11-14 2019-11-14 Stable glucocorticoid formulation

Publications (1)

Publication Number Publication Date
EA202191345A1 true EA202191345A1 (ru) 2021-10-08

Family

ID=68808595

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191345A EA202191345A1 (ru) 2018-11-14 2019-11-14 Стабильный состав глюкокортикоидов

Country Status (13)

Country Link
US (1) US12653891B2 (cg-RX-API-DMAC7.html)
EP (1) EP3706721A1 (cg-RX-API-DMAC7.html)
JP (2) JP7337060B2 (cg-RX-API-DMAC7.html)
KR (2) KR102444113B1 (cg-RX-API-DMAC7.html)
CN (1) CN111918645A (cg-RX-API-DMAC7.html)
AU (1) AU2019378874B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009365A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118505A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191345A1 (cg-RX-API-DMAC7.html)
IL (1) IL283199A (cg-RX-API-DMAC7.html)
MX (1) MX2021005665A (cg-RX-API-DMAC7.html)
SG (1) SG11202104702VA (cg-RX-API-DMAC7.html)
WO (1) WO2020102474A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021247000A1 (en) 2020-06-01 2021-12-09 Avm Biotechnology, Llc Methods of treatment using icam-modulating agents
US12706617B2 (en) 2023-04-27 2026-08-11 Hewlett Packard Enterprise Development Lp Selective filtering to reduce interferences in Wi-Fi communications
US12609718B2 (en) 2023-06-14 2026-04-21 Hewlett Packard Enterprise Development Lp WiFi-7 optimized split band architecture and method of operation
CN116789728B (zh) * 2023-06-16 2026-02-06 山东斯瑞药业有限公司 一种降低糖皮质激素原料药重金属元素杂质含量的工艺
CN116807970A (zh) * 2023-07-26 2023-09-29 遂成药业股份有限公司 一种地塞米松磷酸钠注射液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136607A (en) * 1995-11-02 2000-10-24 Bayer Corporation Multi-analyte reference solutions with stable pO2 in zero headspace containers
US20040197333A1 (en) * 2000-02-10 2004-10-07 Cornell Research Foundation, Inc. Use of TGF-beta antagonists to inhibit tumor cell formation or progression
US9694103B2 (en) * 2003-04-16 2017-07-04 The Children's Hospital Of Philadelphia Photochemical activation of surfaces for attaching biomaterial
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
JP4598484B2 (ja) * 2004-11-11 2010-12-15 テルモ株式会社 塩酸リトドリン注射液製剤
CN101340916A (zh) * 2005-12-22 2009-01-07 兴和株式会社 类固醇的经时稳定性得到改善的外用制剂
AU2013200089B2 (en) * 2006-02-09 2016-03-03 Santen Pharmaceutical Co., Ltd Stable formulations, and methods of their preparation and use
EP2249801A2 (en) 2008-02-07 2010-11-17 Amgen Inc. Stabilized protein compositions
CN101623291B (zh) 2008-07-07 2011-12-07 天津金耀集团有限公司 一种地塞米松磷酸钠注射液
US20110281834A1 (en) * 2008-11-10 2011-11-17 Friden Phillip M Pharmaceutical Formulations for Iontophoretic Delivery of a Corticosteroid
JP2011136973A (ja) * 2009-12-28 2011-07-14 Keiki Imoto 安定なエダラボン含有水性製剤
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
BR112013003169B1 (pt) 2010-08-18 2022-05-24 Theresa Deisher Uso de um agente terapêutico que inibe a ligação de células-tronco a tecido linfóide
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
AU2012204501B2 (en) 2011-01-03 2016-05-19 Avm Biotechnology, Llc Personalized production of biologics and method for reprogramming somatic cells
ITMI20122002A1 (it) 2012-11-26 2014-05-27 Farmacologico Milanese Srl Lab Preparazioni farmaceutiche liquide stabilizzate
JP6741286B2 (ja) * 2013-03-28 2020-08-19 テルモ株式会社 包装されたアセトアミノフェン注射液製剤の製造方法
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
GR1008921B (el) 2015-12-10 2017-01-12 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον δεξαμεθαζονη
CN110475571B (zh) * 2017-04-01 2023-04-04 Avm生物技术有限责任公司 细胞免疫疗法前细胞毒性预调理的替代
CN107375200A (zh) 2017-06-16 2017-11-24 北京立时达药业有限公司 一种地塞米松磷酸钠注射液及其制备方法
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Also Published As

Publication number Publication date
CA3118505A1 (en) 2020-05-22
JP2021514934A (ja) 2021-06-17
KR20200111675A (ko) 2020-09-29
IL283199A (en) 2021-06-30
KR102444113B1 (ko) 2022-09-19
MX2021005665A (es) 2021-09-23
US12653891B2 (en) 2026-06-16
WO2020102474A1 (en) 2020-05-22
JP2023116498A (ja) 2023-08-22
US20200289650A1 (en) 2020-09-17
SG11202104702VA (en) 2021-06-29
BR112021009365A2 (pt) 2021-08-10
AU2019378874B2 (en) 2025-05-29
JP7337060B2 (ja) 2023-09-01
CN111918645A (zh) 2020-11-10
EP3706721A1 (en) 2020-09-16
AU2019378874A1 (en) 2021-06-17
KR20220130253A (ko) 2022-09-26

Similar Documents

Publication Publication Date Title
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
EA201991798A1 (ru) Стабильные при хранении составы
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
JOP20170170B1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
EA201991799A1 (ru) Диспергируемые в воде составы
EA202090448A1 (ru) Дигидрооксадиазиноны
MX2021005665A (es) Formulacion estable de glucocorticoide.
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas
MX2025007537A (es) Composiciones de peptido estables
EA202091471A1 (ru) Полиморфы
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201892500A1 (ru) Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции
EA202190073A1 (ru) Композиции и способы лечения видов гемоглобинопатии и талассемии
EA201992509A1 (ru) Гетероарилфениламинохинолины и аналоги
MX2021014310A (es) Formulaciones de terlipressina.
EA201891905A1 (ru) Стабильная жидкая композиция гонадотропина
ZA202102816B (en) High concentration protein formulation
EA201990560A1 (ru) Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии
MX394833B (es) Formulaciones con mejora de la estabilidad.
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид
MX2023009676A (es) Extractos de corteza de abedul que contienen betulina y su formulacion.
EA202191378A1 (ru) Активные сложноэфирные производные тестостерона, их композиции и применения